Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias.
暂无分享,去创建一个
[1] Stefano Severi,et al. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2017, Cardiovascular research.
[2] D. Sinnecker,et al. Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research , 2017, Current Cardiology Reports.
[3] Response by Crotti et al to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?" , 2016, Circulation. Cardiovascular genetics.
[4] Brian J. Stevenson,et al. TECRL, a new life‐threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT , 2016, EMBO molecular medicine.
[5] T. Meitinger,et al. Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1? , 2016, Circulation. Cardiovascular genetics.
[6] Adriaan P IJzerman,et al. A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells , 2016, EMBO molecular medicine.
[7] S. Yamanaka,et al. A decade of transcription factor-mediated reprogramming to pluripotency , 2016, Nature Reviews Molecular Cell Biology.
[8] Robert Passier,et al. Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology , 2015, EMBO molecular medicine.
[9] Simona Casini,et al. Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? , 2015, Stem cells and development.
[10] Milena Bellin,et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: Disease mechanisms and pharmacological rescue , 2014, Proceedings of the National Academy of Sciences.
[11] Praveen Shukla,et al. Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.
[12] K. Morgan,et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes , 2013, European heart journal.
[13] A. Mehta,et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. , 2014, Cardiovascular research.
[14] Teng Hong Tan,et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.
[15] Lia Crotti,et al. Long-QT syndrome: from genetics to management. , 2012, Circulation. Arrhythmia and electrophysiology.
[16] Jonathan A. Bernstein,et al. Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.
[17] Lior Gepstein,et al. Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.
[18] Karl-Ludwig Laugwitz,et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, The New England journal of medicine.
[19] LimorZwi,et al. Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells , 2009 .
[20] Sean P. Palecek,et al. Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.
[21] Ronald Wilders,et al. Dynamic clamp: a powerful tool in cardiac electrophysiology , 2006, The Journal of physiology.
[22] Carlo Napolitano,et al. Erratum: Long QT syndrome patients with mutations on the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: Implications for gene-specific therapy (Circulation (1995) 92 (3381-3386)) , 1996 .
[23] S. Priori,et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.